Emergent BioSolutions Inc.
EBSFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Emergent BioSolutions Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 10, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| MetLife Investment Management, LLC | 2026-03-31 | 25,237 | $209K | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 744,536 | $6.18M | SEC filing |
| GOLDMAN SACHS GROUP INC | 2026-03-31 | 811,560 | $6.74M | SEC filing |
| Values First Advisors, Inc. | 2026-03-31 | 307,880 | $2.56M | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 353,829 | $2.94M | SEC filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2026-03-31 | 1,506,075 | $12.5M | SEC filing |
| Legal & General Group Plc | 2026-03-31 | 4,587 | $38.1K | SEC filing |
| &PARTNERS | 2026-03-31 | 17,441 | $145K | SEC filing |
| Ancora Advisors LLC | 2026-03-31 | 409,267 | $3.4M | SEC filing |
| Trexquant Investment LP | 2026-03-31 | 524,233 | $4.35M | SEC filing |
| Essential Partners LLC | 2026-03-31 | 1,027 | $8.52K | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 4,341,462 | $36M | SEC filing |
| IFP Advisors, Inc | 2026-03-31 | 137 | $1.14K | SEC filing |
| Herold Advisors, Inc. | 2026-03-31 | 10,000 | $83K | SEC filing |
| Mariner, LLC | 2026-03-31 | 41,095 | $341K | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 335,898 | $2.79M | SEC filing |
| EFG International AG | 2026-03-31 | 1,920 | $15.9K | SEC filing |
| Fortitude Family Office, LLC | 2026-03-31 | 108 | $896 | SEC filing |
| MARTINGALE ASSET MANAGEMENT L P | 2026-03-31 | 66,554 | $552K | SEC filing |
| SILVER OAK SECURITIES, INCORPORATED | 2026-03-31 | 106,700 | $886K | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Emergent BioSolutions Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-10-07 · Glessner Coleen: Larger than 23 of the 24 other insider sales of Common Stock on file. SEC filing
- 2025-03-12 · Fowler Neal Franklin: Larger than all 24 other insider sales of Common Stock on file. SEC filing
- 2024-11-12 · DeGolyer Donald W: Larger than 22 of the 24 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-01 | Zoon Kathryn C · Director | Common Stock | S — Open market or private sale | −16,145 | 8.36 | SEC filing |
| 2026-05-01 | DeGolyer Donald W · Director | Common Stock | S — Open market or private sale | −14,527 | 8.36 | SEC filing |
| 2026-05-01 | Zoon Kathryn C · Director | Common Stock | S — Open market or private sale | −1,057 | 8.97 | SEC filing |
| 2026-05-01 | Dayal Sujata Tyagi · Director | Common Stock | S — Open market or private sale | −980 | 8.94 | SEC filing |
| 2026-05-01 | DeGolyer Donald W · Director | Common Stock | S — Open market or private sale | −954 | 8.96 | SEC filing |
| 2026-05-01 | Dayal Sujata Tyagi · Director | Common Stock | S — Open market or private sale | −12,781 | 8.36 | SEC filing |
| 2026-04-30 | Katkin Keith · Director | Common Stock | S — Open market or private sale | −15,481 | 8.28 | SEC filing |
| 2026-04-01 | Williams Paul Anthony · SVP, Products Business | Common Stock | S — Open market or private sale | −4,000 | 8.44 | SEC filing |
Showing 8 of 11 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-08 | Williams Paul Anthony · SVP, Products Business | Common Stock | F — Payment of exercise price or tax by delivering securities | −694 | SEC filing |
| 2026-06-08 | LINDAHL RICHARD S · EVP, Chief Financial Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −3,964 | SEC filing |
| 2026-06-08 | Hartzel William · SVP, Bioservices | Common Stock | F — Payment of exercise price or tax by delivering securities | −1,741 | SEC filing |
| 2026-06-08 | Glessner Coleen · EVP, Quality & Ethics, and CPL | Common Stock | F — Payment of exercise price or tax by delivering securities | −2,018 | SEC filing |
| 2026-04-30 | Katkin Keith · Director | Stock Options (Right to Buy) | A — Grant, award, or other acquisition | +11,296 | SEC filing |
| 2026-04-30 | DeGolyer Donald W · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +11,296 | SEC filing |
| 2026-04-30 | Katkin Keith · Director | Common Stock | A — Grant, award, or other acquisition | +25,344 | SEC filing |
| 2026-04-30 | Fowler Neal Franklin · Director | Common Stock | A — Grant, award, or other acquisition | +25,344 | SEC filing |
Showing 8 of 22 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-02-25 | LINDAHL RICHARD S · EVP, Chief Financial Officer | Employee Stock Option (Right to buy) | H — Expiration of long derivative position | −20,321 | SEC filing |
| 2026-02-06 | Hartzel William · SVP, Bioservices | Common Stock | D — Disposition to the issuer | −5,771 | SEC filing |
| 2026-02-06 | Glessner Coleen · EVP, Quality & Ethics, and CPL | Common Stock | D — Disposition to the issuer | −28,847 | SEC filing |
| 2026-02-06 | Williams Paul Anthony · SVP, Products Business | Common Stock | D — Disposition to the issuer | −8,655 | SEC filing |
| 2026-02-06 | LINDAHL RICHARD S · EVP, Chief Financial Officer | Common Stock | D — Disposition to the issuer | −46,155 | SEC filing |
| 2025-05-07 | LINDAHL RICHARD S · EVP, Chief Financial Officer | Employee Stock Option (Right to buy) | H — Expiration of long derivative position | −19,963 | SEC filing |
| 2025-02-12 | LINDAHL RICHARD S · EVP, Chief Financial Officer | Common Stock | D — Disposition to the issuer | −16,916 | SEC filing |
| 2025-02-12 | Glessner Coleen · EVP, Quality & Ethics, and CPL | Common Stock | D — Disposition to the issuer | −5,913 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.